Skip to main content
. Author manuscript; available in PMC: 2024 Apr 14.
Published in final edited form as: ACS Infect Dis. 2023 Mar 15;9(4):1004–1021. doi: 10.1021/acsinfecdis.3c00025

Table 3.

PLK1 Inhibitors Show Pf NEK3 Inhibition In Vitroa

compound % activity remaining at 2.5 μM in plasmodial kinases
ARK1 ARK3 CDPK2 CDPK5 GSK3 NEK1 NEK3 PK5 PK6 PK9 PKB
1 100.0 100.0 80.6 100.0 99.4 94.5 4.7 (86 ± 11) 100.0 94.6 97.2 100.0
2 53.4 73.5 100.0 100.0 100.0 93.3 39.6 (1480 ± 150) 100.0 94.8 100.0 64.2
11 100.0 83.6 100.0 100.0 100.0 93.8 11.1 (130 ± 20) 100.0 67.3 100.0 49.3
12 99.5 96.2 100.0 100.0 100.0 100.0 9.7 (19 ± 30) 100.0 100.0 100.0 100.0
18 73.9 84.6 24.0 (390 ± 50) 88.1 100.0 96.4 15.4 (630 ± 120) 100.0 78.9 78.7 12.3 (250 ± 60)
19 77.9 83.6 36.1 (780 ± 90) 100.0 100.0 90.1 18.5 (1820 ± 210) 100.0 91.0 85.7 14.8 (790 ± 140)
a

Values are % activity remaining.

Values in parentheses are IC50 values in nM ± SD.